Interferon beta-1a

An interferon beta-1 subtype that has a methionine at position 1, a cysteine at position 17, and is glycosylated at position 80. It functions as an ANTI-VIRAL AGENT and IMMUNOMODULATOR and is used to manage the symptoms of RELAPSING-REMITTING MULTIPLE SCLEROSIS.

Also Known As:

Networked: 635 relevant articles (66 outcomes, 237 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kappos, Ludwig: 18 articles (01/2022 - 10/2007)
2.	Hartung, Hans-Peter: 17 articles (11/2019 - 09/2005)
3.	Havrdova, Eva: 15 articles (10/2019 - 10/2007)
4.	Rudick, R A: 15 articles (04/2016 - 12/2000)
5.	Margolin, David H: 14 articles (01/2021 - 10/2008)
6.	Comi, Giancarlo: 13 articles (01/2022 - 10/2004)
7.	Selmaj, Krzysztof W: 13 articles (01/2021 - 10/2008)
8.	Giovannoni, Gavin: 13 articles (01/2018 - 10/2004)
9.	Arnold, Douglas L: 12 articles (01/2021 - 11/2012)
10.	Cohen, Jeffrey A: 12 articles (11/2019 - 02/2010)

Related Diseases

1.	Relapsing-Remitting Multiple Sclerosis 01/01/2005 - "Subcutaneous recombinant interferon-beta-1a (Rebif) 22 or 44 microg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis. " 01/01/2005 - "Subcutaneous recombinant interferon-beta-1a (Rebif) 22 or 44 microg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis (RRMS). " 12/01/1998 - "Recombinant interferon-beta-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis." 01/01/2020 - "This study evaluated efficacy of subcutaneous (sc) interferon beta-1a (IFN β-1a) 44 µg 3 × weekly (tiw) in patients appearing to transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS). " 10/01/1999 - "The aim of the study was to evaluate the efficacy of interferon beta-1a (IFN-beta-1a) and beta-1b (IFN-beta-1b) in clinical practice for the treatment of relapsing-remitting multiple sclerosis (RR MS). "
2.	Multiple Sclerosis 01/01/2022 - "In the REFLEX trial (ClinicalTrials.gov identifier: NCT00404352), patients with a first clinical demyelinating event (FCDE) displayed significantly delayed onset of multiple sclerosis (MS; McDonald criteria) when treated with subcutaneous interferon beta-1a (sc IFN β-1a) versus placebo. " 03/01/2006 - "Taken together, these data indicate that patients may benefit from early treatment; the positive results of three double-blind placebo-controlled clinical trials (Early Treatment of Multiple Sclerosis and Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study and BENEFIT) support this conclusion." 06/01/2000 - "Taken together, these data indicate that patients may benefit from early treatment; the positive results of the Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study support this conclusion." 09/28/2000 - "Initiating treatment with interferon beta-1a at the time of a first demyelinating event is beneficial for patients with brain lesions on MRI that indicate a high risk of clinically definite multiple sclerosis." 06/01/2012 - "This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple sclerosis, in healthy volunteers. "
3.	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 02/23/2010 - "Because IM interferon beta-1a (IM IFNbeta-1a) is an effective and safe treatment for MS, we conducted a dose-ranging efficacy study of IFNbeta-1a in patients with CIDP. " 07/13/1999 - "To test the safety and efficacy of interferon beta-1a (IFN-beta) in treatment-resistant chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). " 07/13/1999 - "Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy." 02/23/2010 - "Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy." 04/01/2003 - "Interferon beta-1a as an investigational treatment for CIDP."
4.	COVID-19 01/01/2021 - "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial." 12/01/2021 - "Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trial." 10/26/2020 - "We will investigate the effectiveness of high dose Interferon Beta 1a, compared to low dose Interferon Beta 1a (the base therapeutic regimen) in COVID-19 Confirmed Cases (Either RT-PCR or CT Scan Confirmed) with moderate to severe disease TRIAL DESIGN: This is a single center, open label, randomized, controlled, 2-arm parallel group (1:1 ratio), clinical trial. " 08/01/2020 - "Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial." 10/01/2021 - "Interferon-beta 1a (IFN-β 1a) has been used to treat patients with COVID-19. "
5.	Chronic Progressive Multiple Sclerosis 10/13/2004 - "This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled trial of Interferon beta-1a in subjects with PPMS. " 05/01/2004 - "Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis." 06/01/2001 - "The 436 patients enrolled in the International Multiple Sclerosis Secondary Progressive Avonex Controlled Trial underwent 3 prebaseline MSFC testing sessions before randomization. " 01/01/2017 - "Using the International Multiple Sclerosis Secondary Progressive Avonex Clinical Trial (IMPACT) placebo arm ( n = 215) data, we analyzed disability progression using a novel progression endpoint, "EDSS-Plus," defined as progression on ⩾1 of 3 components (EDSS, T25FW, and/or 9HPT) confirmed ⩾24 weeks apart and with a ⩾20% minimum threshold change for T25FW and 9HPT. " 11/21/2015 - "Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis."

Related Drugs and Biologics

1.	Interferon beta-1a
2.	Natalizumab (Tysabri)
3.	Alemtuzumab (Campath)
4.	Fingolimod Hydrochloride (FTY720)
5.	Interferon beta-1b (Betaseron)
6.	Interferons
7.	Interferon-beta
8.	Methylprednisolone
9.	Daclizumab (Zenapax)
10.	ozanimod

Related Therapies and Procedures

1.	Therapeutics
2.	Telescopes
3.	Injections
4.	Aftercare (After-Treatment)
5.	Subcutaneous Injections